Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS
Recruiting
Observational Study
Liver Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Liver cancer (LC) is the sixth most common malignant tumor and the third cause of cancer mortality in the world. According to the 2018 United States Association for the Study of Liver Diseases guidelines for the diagnosis and treatment of liver cancer, patients with HCC high-risk factors can be directly diagnosed by imaging if they have typical imaging signs, without the need for puncture patholog…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. High-risk groups of HCC: patients with liver cirrhosis or chronic viral hepatitis B, or patients who have been diagnosed with HCC or have a history of HCC in the past, as well as adult liver transplant patients and follow-up patients after liver transplantation;
2. CEUS and c…
Contacts